30 closest matches · ranked by relevance
Upper Gastrointestinal Mucosal Damage
Primary: Incidence of Subjects With Gastroduodenal Erosions and Ulcers. — 72; 54; 19; 36 participants
Inflammatory Bowel Diseases
Primary: Mucosal Impedance Values — 1139; 849; 891; 783 ohms
Gastroduodenal Ulceration
Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants
Gastrointestinal Mucosal Damage
Primary: Gastromucosal Damage (GMD) Score of Paracetamol Tablet vs Ibuprofen Capsule — 0.33; 1.48 Scores on a scale — p=<0.0001
Capsule Endoscopy
Primary: Circumferential Visualization of the Z-line — 0; 5; 5; 7 Participants
Gastrointestinal Lesions · Signs and Symptoms, Digestive
Primary: GI Mucosal Lesions Change and Clinical Symptoms Using The Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.99; 2.19 GSRS score — p=0.05
Upper GI Bleeding
Primary: Number of Participants With True Positive Results — 3 Participants
Healthy Conditions
Primary: Mucosal Surface Enlargement — 10.2; 9.9 percentage of muscular mucosae — p=<0.05
Injury of Duodenum · Pancreatic Injury
Primary: Duodenal-related Complications — 13; 11; 8; 19 percentage of subjects
Stress Ulcer Prophylaxis
Primary: The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase — 2.7; 4.6 % of participants — p=0.393
Erosive Gastritis
Primary: Changes in Erosions — 4.36; 3.38; 2.32; 2.43 erosions
Peptic Ulcer
Primary: Number of Participants Completing Natural Orifice Translumenal Endoscopic Surgical (NOTES) Repair — 2; 1 participants
Gastroduodenal Ulcerations · Erosion
Primary: Degree of GI Injury at Day 15 — 23; 20; 11; 13 participants
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
UGI Bleeding · Ulcer or Variceal Hemorrhage · Stigmata of Recent Hemorrhage
Primary: 30 Day Rebleeding Rate — 20; 8; 17; 6 Participants
Gastro Intestinal Bleeding · Hematemesis · Melena
Primary: Rate of Detection of Bleeding — 11; 11 Participants
Stomach Neoplasms · Metaplasia
Primary: Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy — 78.5; 94.4; 89.2; 67.1 percentage of lesions
Fabry's Disease
Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours
Gastrointestinal Lesions
Primary: Endoscopic Score - Cryer Score — 4; 4 Cryer score
Abdominal Pain · Gastritis · Gastric Ulcer
Primary: Number of Participants With Visualization of All Major Anatomic Regions in the Stomach With MCCE Based on 2 Reviewers — 37; 39; 39; 36 participants
Polyp of Colon · Fistula
Primary: Time to Closure — 23.3; 18.4 minutes
Gastroesophageal Reflux Disease
Primary: Protection Against DNA Damage by UDCA — 1.068; .82 Relative Densitometry Units
Crohn Disease
Primary: Change From Baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) Blinded Score at Week 6 — -4.8 Score on a scale
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
Eosinophilic Esophagitis
Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms
Gastrointestinal Cancer
Primary: Serious Adverse Events — 0 Participants
Autoimmune Disease
Primary: Changes in GI Symptom Severity After Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) — 2.28; 2.02; -0.28 Scores on a scale
Critical Illness
Primary: Perfused Boundary Region (PBR) in One Week — 1.95; 1.97; 2.02 micrometer
Gastro-esophageal Reflux Disease
Primary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change